Bio Essence (BIOE) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 41 59 sessions, October 31, 2025 to October 30, 2026
- Largest daily move
- +201.5% close of March 19, 2026
- 1-month change
- +158.4% closing prices, September 8, 2026 to October 30, 2026
Company Description
Bio Essence Corp. is an operating company whose common stock trades under the symbol BIOE and whose public-company materials describe a business focused on wellness and vitality through holistic products and practices. The company also describes growth strategies that include AI-enabled platform initiatives connected to health and wellness markets.
Bio Essence presents its business around two durable themes: a wellness-oriented operating identity and an emerging technology growth strategy. Its wellness description centers on lifestyle practices and holistic products, while its platform strategy refers to AI-enabled initiatives that may expand the company's activities beyond its existing core operations. The company's disclosures and public announcements also refer to capital-raising activity, material agreements, governance matters, and capital-structure topics.
The company is based in Irvine, California. Bio Essence announced approval for an upgrade to the OTCQB Venture Market, with its common stock trading under the BIOE ticker. The OTCQB status places the company within a market designed for entrepreneurial and development-stage issuers that maintain current reporting, annual verification, management certification, minimum bid standards, and governance requirements.
Stock Performance
Bio Essence (BIOE) closed at $0.4700 on October 30, 2026. Over the past month, the price has gained 158.4%.
BIOE Metrics & Rankings
Price returns through October 30, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Bio Essence has 6 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 1 with negative movement. Key topics include AI, acquisition, offering. View all BIOE news →
SEC Filings
Bio Essence has filed 10 recent SEC filings, including 3 Form 10-Q, 2 Form 8-K, 1 Form 144, 1 Form PRE 14C. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all BIOE SEC filings →
Financial Highlights
Bio Essence generated $1.9M in revenue in FY2025, retaining a 75.3% gross margin, operating income reached $900K (47.4% operating margin), and net income was $896K, reflecting a 47.2% net profit margin. Diluted earnings per share stood at $0.02. The company generated $1.6M in operating cash flow. The current ratio was 0.17, measuring current assets divided by current liabilities.
Upcoming Events
MediFlow development completion
Bio Essence has 1 upcoming scheduled event. The next event, "MediFlow development completion", is scheduled for December 15, 2026 (in 39 days). Investors can track these dates to stay informed about potential catalysts that may affect the BIOE stock price.
Short Interest History
Short interest in Bio Essence (BIOE) currently stands at 357 shares, a new position with no short interest reported in the previous period, representing 0.0% of the float. Since March 2026, short interest has decreased by 94.7%.
Days to Cover History
Days to cover for Bio Essence (BIOE) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume.
BIOE Company Profile & Sector Positioning
Bio Essence (BIOE) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC.
Investors comparing BIOE often look at related companies in the same sector, including Captiva Verde Wellness Co (CPIVF), Radnostix Inc (INIS), Earth Science Tech Inc (ETST), Planet 13 Holdings Inc NEV (PLNH), and BioNxt Solutions Inc (BNXTF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate BIOE's relative position within its industry.